Thyroxine (T4) may promote re-epithelialisation and angiogenesis in wounded human skin ex vivo

Guo-You Zhang1*, Ewan A. Langan2,3*, Natalia T. Meier4, Wolfgang Funk5, Frank Siemers6, Ralf Paus7,8*

1 Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 2 Department of Dermatology, University of Lübeck, Lübeck, Germany, 3 Centre for Dermatology Research, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 4 Department of Pathology, University of Lübeck, Lübeck, Germany, 5 Klinik Dr. Funk, Munich, Germany, 6 Department of Plastic and Hand Surgery, BG Klinikum Bergmannstrost, Halle/Saale, Germany, 7 Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, United States of America, 8 Centre for Dermatology Research, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

* These authors contributed equally to this work.

Abstract

There is a pressing need for improved preclinical model systems in which to study human skin wound healing. Here, we report the development and application of a serum-free full thickness human skin wound healing model. Not only can re-epithelialization (epidermal repair) and angiogenesis be studied in this simple and instructive model, but the model can also be used to identify clinically relevant wound-healing promoting agents, and to dissect underlying candidate mechanisms of action in the target tissue. We present preliminary ex vivo data to suggest that Thyroxine (T4), which reportedly promotes skin wound healing in rodents in vivo, may promote key features of human skin wound healing. Namely, T4 stimulates re-epithelialisation and angiogenesis, and modulates both wound healing-associated epidermal keratin expression and energy metabolism in experimentally wounded human skin. Functionally, the wound healing-promoting effects of T4 are at least partially mediated via fibroblast growth factor/fibroblast growth factor receptor-mediated signalling, since they could be significantly antagonized by bFGF-neutralizing antibody. Thus, this pragmatic, easy-to-use full-thickness human skin wound healing model provides a useful preclinical research tool in the search for clinically relevant candidate wound healing-promoting agents. These ex vivo data encourage further pre-clinical testing of topical T4 as a cost-efficient, novel agent in the management of chronic human skin wounds.
Introduction

Retarded healing of human skin wounds, which may result in ulceration, represents an increasing, global healthcare and quality-of-life challenge, especially in the context of an aging population [1–5]. Indeed, there is a pressing need for the identification of effective, safe and cost-efficient wound healing promoters which can be introduced into clinical practice [6]. In order to meet this need, it is critical to have simple and pragmatic, predictive model systems in which new candidate promoters of human skin wound healing can be instructively studied at the preclinical level [7, 8]. Though modelling wound healing in so-called 3D skin “equivalent” culture systems is informative [9], such systems usually lack skin appendages, immune cells, for example macrophages and mast cells, and other resident skin cells, and do not reflect the tissue tension characteristics of human skin, all of which are already known to significantly modulate cutaneous wound healing [10–16]. Therefore, we and others have advocated the use of experimentally wounded full-thickness human skin \textit{ex vivo}, ideally under defined, serum-free organ culture conditions, as well as the systematic testing of agents that have already been licensed for clinical use [7].

Thyroid hormones (THs) are of special interest in this context, since human skin and hair follicles are classical TH target organs [17–27], while thyroid diseases affect skin structure and function on multiple levels [28–30]. For example, L-thyroxine (T4) promotes human hair growth [19] and stimulates wound healing \textit{in vivo} in rats [31] and mice [32]. Moreover, T4 operates as the chief endocrine control of amphibian metamorphosis [33], suggesting that it can act as a powerful morphogen. In addition, T4 is one of the most frequently administered hormones in clinical medicine, where it has been in extensive use for decades, its toxicology is very well-examined [34], and it is relatively inexpensive. Yet, the potential clinical utility of T4 in a dermatological setting, namely as a candidate wound healing promoter, is yet to be fully explored [30].

Given the reported wound healing-promoting properties of T4 in rodents [31, 32] and the strong interdependence of cutaneous wound healing, hair follicle (HF) cycling, HF neogenesis and skin stem cell activities [35–37], we hypothesized that T4 may also promote human skin wound healing. In order to probe whether T4 directly impacted on human skin wound healing, i.e. in the absence of other systemic/endocrine inputs, we tested our hypothesis in serum-free organ culture of full-thickness human skin [38] that had been experimentally wounded, using a “punch-in-a-punch” design [7, 39].

Recognizing that re-epithelialisation and angiogenesis are key determinants of physiological cutaneous wound healing [10, 37, 40–42] we primarily assessed T4 effects on the regenerated epidermis (“epithelial tongues” [ET]) at the inner and outer edges of wounded skin fragments [7, 43] and on intradermal angiogenesis (see Fig 1). Re-epithelialisation can be instructively quantified by planimetric measurement of both the mean length (as an indicator of keratinocyte migration) and the combined areas of the inner and outer ET (as an indicator of total epithelial regeneration) [7] (Fig 1a–1g).

Evidence for angiogenesis was assessed by quantitative CD31 immunohistomorphometry, namely CD31 immunoreactivity (IR) and the number of CD31 positive cells and cross-sectional lumina [44]. In addition, we measured the IR of basic fibroblast growth factor (bFGF, FGF2) since this pro-angiogenic growth factor is up-regulated by T4 [45, 46] and is known to play a key role as positive regulator of wound healing [47–52]. Finally, we also assessed how T4 impacts on the key wound healing associated keratin 6 (CK6) [7, 53, 54].

Material and methods

Williams’ E medium (Biochrom, Cambridge, UK) supplemented with 2 mmol/liter L-glutamine (Invitrogen, Paisley, UK), 10 ng/ml hydrocortisone (Sigma-Aldrich, Taufkirchen,
Germany), 10 μg/ml insulin (Sigma), and antibiotic mixture (100 U/ml Penicillin, 10 microg/ml Streptomycin) (Sigma-Aldrich, Taufkirchen, Germany) [19, 55]. Thyroxine (T4) was obtained from Sigma. Goat polyclonal bFGF-neutralizing antibody [45] was obtained from R&D systems, Minneapolis, MN (anti-FGF basic Antibody, AB-233-NA).

Skin samples

Human scalp or corporal skin samples were obtained from patients undergoing plastic or reconstructive surgical procedures with informed consent and Institutional Research Ethics Committee permission (University of Luebeck: 06–109). The study was conducted according to The Helsinki Declaration of 1975 (revised 1983). Our study included samples from 6 patients aged from 26–67 years (average 52.6 years) (details, see Table 1).

Table 1. Characteristics of patients included in this study.

| Patient | Age (years) | Sex | Location |
|---------|-------------|-----|----------|
| Patient 1<sup>a</sup> | 67 | F | Temporal |
| Patient 2<sup>a</sup> | 42 | F | Breast |
| Patient 3<sup>a</sup> | 59 | F | Forearm |
| Patient 4<sup>a</sup> | 61 | F | Face |
| Patient 5<sup>b</sup> | 61 | F | Temporal |
| Patient 6<sup>b</sup> | 26 | M | Buttock |

<sup>a</sup>: used for T4 experiment analysis;
<sup>b</sup>: used for inhibitory bFGF antibody treatment experiments
Human skin wound healing organ culture model

The human skin wound healing assay modified based on the previously published “punch-in-a-punch” design [7, 8, 39] with the notable difference being that full-thickness (including subcutaneous fat) adult human skin was used and cultured in serum-free medium [38] (Fig 1). In the pilot study reported here, one to two “punches” were obtained for each experimental condition (control, T4 10, 100 or 1000nM) from each patient at the beginning of each culture and snap frozen at day 3 or 6 depending on the experimental group. Samples were frozen immediately for analysis (day 0) or transferred to six-well plates containing supplemented Williams E culture medium [38]. Each well contained 1–2 skin punches in 3 ml of medium. Skin samples were left untreated (“equilibration period”) for the first 24 hours of the culture period. Then the medium was replaced for all samples; in the test conditions T4 was tested at concentrations ranging from 10 to 1000 nM, based on our previous human HF organ culture study [19]. Control and T4 supplemented culture medium were changed every 2 days and sample freezing was performed as per the culture protocol (Fig 1). Human skin fragments were embedded in Shandon Cryomatrix (Thermo Fisher Scientific; Waltham, MA, USA) before longitudinal cryosections (6μm) were obtained. Cryosections were stored at -80°C until used.

Immunohistochemistry, immunofluorescence and quantitative immunohistomorphometry

The antibodies and corresponding detection methods which were used are described in Table 2. For detection of proliferating and apoptotic cells in this system, Ki67/TUNEL quantitative-immunohistomorphometry was performed as described previously [19, 23, 24, 36, 38, 56–58]. For the quantitative evaluation of the double-immunostaining results, DAPI-, Ki67-, or TUNEL-positive cells were counted in defined reference areas (see dotted line) in the newly regenerated epidermis (ETs), (Fig 1). The number of DAPI-positive cells served as “total number of cells”, and the percentage of Ki-67-positive and/or TUNEL positive cells was calculated on this basis to enable comparison between control and test groups.

Standard haematoxylin and eosin staining was used to determine the new ETs. Cytokeratin 6, CD31, bFGF, and fibroblast growth factor receptor 1 (FGFR1) immunofluorescence were detected using the previously described methods [7, 19, 44, 59]. Mitochondrially encoded cytochrome c oxidase 1 (MTCO1) IR was detected by peroxidase-based avidin-biotin complex immunostaining, without counterstaining with Haematoxylin. A monoclonal antibody that

Table 2. Antibodies used for immunohistology.

| Name    | Host    | Dilution | Method | Source                                              | Positive control                                                                 | Clone   |
|---------|---------|----------|--------|----------------------------------------------------|-----------------------------------------------------------------------------------|---------|
| MTCO1   | Mouse   | 1:50     | AEC    | Mitosciences, Eugene, OR, USA                      | Skin epidermis [60, 61]                                                          | 1D6E1A8 |
| Keratin 6 | Mouse | 1:10     | Indirect IF | PROGEN, Heidelberg, Germany                      | Suprabasal layers of the ORS; suprabasal layers of wounded skin [63, 79]          | Ks6, KA12 |
| bFGF    | Mouse   | 1:50     | Indirect IF | Abcam, Cambridge, UK                            | Epidermis [59]                                                                  | ab181   |
| FGFR1   | Mouse   | 1:100    | Indirect IF | Abcam, Cambridge, UK                            | Epidermis [59]                                                                  | ab829   |
| PCAM (CD31) | Mouse | 1:30     | Indirect IF | Dako, Glostrup, Denmark                         | Dermal microvessels [44]                                                          | M0823   |

MTCO1: cytochrome c oxidase 1; IF: immunofluorescence; TSA: Tyramide Signal Amplification; PECAM: Platelet Endothelial Cell Adhesion Molecule; CTS: connective tissue sheath

https://doi.org/10.1371/journal.pone.0212659.t002
selectively recognizes the mitochondria-specific complex IV subunit of cytochrome oxidase \( c \) was employed. \[26, 27, 60, 61\]. We had previously documented that the intensity of keratino-
cyte MTCO1 IR *in situ* correlates with the activity of respiratory chain complexes I and IV \[26, 27, 60\]. Given that the angiogenic effects of T4 may be mediated via upregulation of FGFR \[45, 52\], we cultured 1–2 "punches" of skin with either 100nM T4 or 100nM T4 plus inhibitory bFGF (8μg/ml) antibody in short-term organ culture for 3 days.

For quantitative immunohistomorphometry \[23, 24, 56–58\], the IR in the ETs was analysed. Both outer and inner epithelial tongue were analysed, defined as the area from the edge of the stratum corneum where the punch had been placed to the corresponding point in the epider-
mal basal layer. For the angiogenesis parameters, CD31 IR, the number of CD31 positive
nuclei and the number of vessel lumina were determined as previously described \[44\]. The
Image J software (National Institute of Health, Bethesda, MD) was used for evaluation. All the
samples were photographed for analysis with a Keyence Biozero-8000 Microscope (Keyence
Corporation, Higashi-Nakajima, Osaka, Japan).

**Statistical analysis**

All the data are given as mean ± standard error of the mean (SEM). For the quantitative immu-
nohistomorphometry analyses, the IR in the ETs was measured in up to 4 sections for each
wounded skin fragment. One-Way ANOVA by appropriate post hoc comparisons was used at
single time points, and if the data did not follow a Gaussian distribution, non-parametric tests
were applied (i.e. Kruskal-Wallis test). Statistical analysis was carried out by Graphpad prism
5.01 (Graph Pad software, Inc., San Diego, CA, USA), and \( p<0.05 \) was regarded as significant.

**Results**

After wounding, a compact sheet of epidermal keratinocytes (the ETs) began to cover the
wound edges in all groups (epiboly phenomenon \[62\]), as expected \[21\]. Histochemically,
overall skin morphology was well-preserved until and including day 6 of organ culture, during
which time no epidermal detachment from the basal membrane was seen, while the number of
proliferating or apoptotic keratinocytes in the epidermis and HFJs (Ki-67/TUNEL immunoflu-
orescence microscopy) during the entire study window of 6 days was within the expected nor-
mal range \[26, 38\].

Compared to the vehicle control, T4 administered to the culture medium significantly stim-
ulated re-epithelialisation by day 3 after skin wounding in organ culture (Fig 2a–2d). Thereaf-
ter, higher concentrations of T4 rather slowed-down ET elongation (possibly due to an
inhibition of keratinocyte migration). However, the total ET area (i.e. the mass of regenerated
epithelium) was persistently larger in T4-treated compared to vehicle-treated wound skin frag-
ments *ex vivo* (Fig 2a–2d).

Proliferation and apoptosis in the ETs were not significantly modulated by T4 (only high-
dose T4 treatment showed a [non-significant] proliferation-stimulatory trend in the ETs at
day 3), as measured by quantitative immunohistomorphometry of Ki67+ or terminal deoxynu-
cleotidyl transferase dUTP nick end labelling-positive (TUNEL+) cells in ETs (Fig 2e–2h).
This may reflect the well-recognized complexity of T4’s effects on the overall tissue modelling
process, which represents a balance of keratinocyte proliferation, apoptosis, differentiation
and migration effects \[33\]. This observation suggests that the re-epithelialisation-promoting
effects of T4 primarily result from the stimulation of keratinocyte migration.

T4 also significantly increased expression of the major wound healing-associated keratin,
keratin 6 \[53, 63\] (Fig 2i and 2j), and of the mitochondrial activity protein marker, MTCO1
Fig 2. T4 promotes human skin re-epithelialisation. (a-d) Haematoxylin and eosin histochemistry: overview of wounded human skin fragment. After 3 days, epithelial tongue areas (black dotted line area) (ET) and length (blue dotted line) were significantly greater after treatment with T4 compared to control alone. (e-h) Cryosections of control-, or T4-treated human skin were examined by Ki-67 (red arrow)/TUNEL (green arrow) double-labelling [19, 23, 24, 56, 57] (e, f). The percentage of positive cells was analyzed in the new ETs (see dotted line). When compared to the control group, more Ki-67 positive cells after 3 day culture with 1000 nM T4 treatment (and more TUNEL positive cells at day 3 in T4 1000 nM treated group were found, although the differences were not statistically significant (e-h). (i, j) CK6 expression was significantly upregulated by T4, especially in the 1000 nM treatment group. Green fluorescence staining represented cytokeratin 6 IR in the new wound ET (dotted line area). (k, l) MTCO1 expression was significantly up-regulated by T4. Brown staining represents MTCO1 IR in the new ET. Staining intensity was measured in a defined reference area (dotted line) and normalized to the control (100%), as for CK6 expression. Number of independent experiments: n = 3 subjects (i.e. 1–2 punches per patient, per treatment group and per time point and at least 8 photomicrographs were analysed per condition); data were pooled since the results trends in all three independent experiments were comparable. *p<0.05, **p<0.01, ***<0.001. Scale bars = 50µm.

https://doi.org/10.1371/journal.pone.0212659.g002

[60, 61] (Fig 2k and 2l), whose expression is well-correlated with respiratory chain complexes I and IV activity in human epidermis [26, 60, 61].

Furthermore, T4 treatment moderately increased CD31 IR, the number of CD31+ positive endothelial cells in T4-treated wounded skin fragments (Fig 3a–3e) and the microvessel density (Fig 3a, 3b and 3f), measured as described previously [44]. This suggests that T4 enhanced angiogenesis in wounded human skin fragments ex vivo, despite the fact that these cutaneous
blood vessels are non-perfused and may collapse to some degree after surgical skin removal. Whilst the effect was modest, it was statistically significant.

Since bFGF is a key pro-angiogenic factor known to be up-regulated by T4 [45, 46], we further examined the role of this growth factor role in T4-stimulated wounded human skin. Indeed, T4 increased bFGF protein IR in the ETs (Fig 4a–4c). Next, FGFR1 IR was assessed, since the proangiogenic actions of T4 may be indirectly mediated at least in part via up regulating FGFR1 expression [64]. In fact, as shown in Fig 4d–4f, FGFR1 was significantly increased in ETs by T4 compared to control.

Most importantly, co-administration of inhibitory-bFGF antibody [45] counteracted the stimulatory effects of T4 on re-epithelialisation (Fig 5a and 5b), CD31 protein IR (Fig 5c), and number of CD31+ endothelial cells (Fig 5d), microvessel density (Fig 5e) and bFGF expression (Fig 5f). Taken together, this suggests that the wound healing-promoting effects of T4 in organ-cultured human skin are, at least in part, bFGF-dependent.

Discussion

Here we report how organ-cultured, experimentally wounded human skin can be used to identify clinically relevant wound-healing promoting drugs, and to dissect underlying candidate mechanisms of action. The main advantage of the current model is its use of full-thickness human skin (which is readily available as excess tissue from plastic surgery) in a serum-free setting. Thus, not only the interaction between the epidermis, dermis and subcutaneous tissue is preserved, but the skin appendages, including intact HFs and sweat glands, all of which may play a substantial role in wound healing [37, 65, 66] are also present. In contrast to 3D skin culture models, it is therefore potentially possible to study the influence of the full range of resident skin cell populations on cutaneous wound healing. Future work may utilise the model to
carefully study the influence of the HF on wound healing in human skin \textit{ex vivo}. Notably, we show \textit{ex vivo} data to suggest that T4, a widely used, cost efficient drug with well-known toxicology, may promote key features of human skin wound healing.

The model also enables selected skin signalling pathways to be studied, just as in serum-free human HF organ culture [67–69]. Namely, provide preliminary preclinical evidence that the re-epithelialisation- and angiogenesis-promoting effects of T4 in experimentally wounded human skin \textit{ex vivo} primarily are due to the up-regulation of bFGF/FGFR1-mediated signalling in the wounded epithelium.

Of course, it is important to also recognize the limitations of the \textit{ex vivo} model used here. These limitations include, besides the obviously missing functional skin innervation and perfusion, the relatively short time-frame in which wound healing can be studied here. After approximately 6 days, epidermal detachment becomes a prominent feature, preventing long-term application of the model. For this reason we limited the culture time to avoid confounding the data by increasing tissue degeneration effects, and thus focused on early to medium-term interventions to promote wound healing. Another important limitation is that we used skin explants from skin containing either terminal or vellus HFs. Recently studies have confirmed the superior wound healing promoting properties of hair-bearing skin when compared...
to skin from “hair-free” sites [65]. Whether T4 would exert superior wound healing promoting properties in terminal hair-bearing skin compared to skin dominated by vellus HFs or hair-free palmoplantar skin remains to be clarified. It must also be borne in mind that the thyroid-status of the subjects at the time of surgery was not known.

To consolidate the pilot results reported here, it is important that the current study is repeated both, with skin from an increased number of subjects and in additional wound healing models, including, for example humanized mouse in vivo models of wound healing [70] to confirm the positive effect of T4 on wound healing. Such pre-clinical testing is essential given the possible side-effects of topical T4 application in human subjects, included systemic absorption which might lead to a hyperthyroid state, a key consideration as increased T4 serum levels are strictly to be avoided. Reassuringly though, topical T4 may fail to influence circulating T4 levels significantly [71]. Whether the absence of perfusion-derived endocrine signalling ex vivo may render organ-cultured skin “functionally” hypothyroid and whether this is compensated for by increased intracutaneous conversion of residual T4 to tri-iodothyronine [19] is unknown.

Fig 5. (a-f) T4 mediates its effect at least partially via bFGF. T4 exerts its effect partly through inducing bFGF at day 3. Area and length of the ET (a: length of new ET; b: area of new ET), intensity of the IR of CD31 (c), number of CD31+ cells (d), Number of CD31+ lumina (e), and intensity of IR of bFGF in new ET (f) were significantly increased in the T4-treated test group compared to controls. 1–2 punches per patient, per treatment group and per time point and at least 8 photomicrographs were analyzed per condition. These effects could be abrogated by co-treatment with inhibitory bFGF antibody [45].

https://doi.org/10.1371/journal.pone.0212659.g005
Caution must be exercised with extrapolating the effects of T4 on human skin healing *ex vivo* to the more complex *in vivo* situation, as the model does not satisfactorily permit the study of the important contributions of platelets, neutrophils and circulating T cells to wound healing [72, 73]; while resident immunocytes like mast cells and macrophages are abundantly present and can be instructively studied *ex vivo* [74–77] Yet, the *ex vivo* effects of T4 reported here are well in line with its *in vivo* effects reported in rodent wound healing models [22, 31, 32]

Given the overall medical importance of wound healing disorders and the urgency to develop more effective, affordable, and safe wound healing-promoting agents for the treatment of chronic skin ulcers [7, 78]. Our pilot data encourage the preclinical systematic exploration of T4 as a potential wound healing promoter in experimentally wounded human skin, using additional wound healing models [8] as the next step before determining whether T4 is a plausible future skin ulcer therapy.

**Supporting information**

S1 Table. (Immuno)histochemical evaluations.

(XLSX)

**Acknowledgments**

Most of the work reported here was performed while GYZ, EAL, NM and RP worked jointly in the Department of Dermatology, University of Lübeck. The experiments were formed/data were generated by GYZ, with help from NM. EAL and RP contributed to data analysis and manuscript writing. FS and WF provided human tissue samples and helped with manuscript editing. The excellent technical assistance of Gabriele Scheel and Claudia Kremling and the help of Dr. Tian Liao with evaluations are gratefully acknowledged as is the contribution of Dr. M. Geissen (UKE, Hamburg). This work was supported in part by a grant from the Federal Ministry of Economics, Germany (AiF/ZIM Programme) to R.P. G-Y Zhang was supported by a Chinese government award for outstanding self-financed students abroad (China Scholarship Council) and the National Natural Science Foundation of China (81101430).

**Author Contributions**

**Conceptualization:** Ralf Paus.

**Data curation:** Guo-You Zhang, Ralf Paus.

**Formal analysis:** Guo-You Zhang, Natalia T. Meier, Ralf Paus.

**Funding acquisition:** Ralf Paus.

**Investigation:** Guo-You Zhang.

**Methodology:** Guo-You Zhang, Natalia T. Meier, Ralf Paus.

**Project administration:** Guo-You Zhang, Ralf Paus.

**Resources:** Wolfgang Funk, Frank Siemers, Ralf Paus.

**Supervision:** Natalia T. Meier, Ralf Paus.

**Validation:** Guo-You Zhang, Natalia T. Meier, Ralf Paus.

**Visualization:** Guo-You Zhang.

**Writing – original draft:** Guo-You Zhang, Ewan A. Langan, Natalia T. Meier, Ralf Paus.
Writing – review & editing: Guo-You Zhang, Ewan A. Langan, Natalia T. Meier, Wolfgang Funk, Frank Siemers, Ralf Paus.

References

1. Ilonzo N, Patel M, Lantis JC 2nd. Managing the Diabetic Foot Ulcer: How Best Practices Fit the Real 2018 United States. Surg Technol Int. 2018; 32:49–59. Epub 2018/04/04. PMID: 29611155.

2. Guest JF, Fuller GW, Vowden P. Venous leg ulcer management in clinical practice in the UK: costs and outcomes. Int Wound J. 2018; 15(1):29–37. Epub 2017/12/16. https://doi.org/10.1111/iwj.12814 PMID: 29243398.

3. Coleman S, Smith IL, McGinnis E, Keen J, Muir D, Wilson L, et al. Clinical evaluation of a new pressure ulcer risk assessment instrument, the Pressure Ulcer Risk Primary or Secondary Evaluation Tool (PURPOSE T). J Adv Nurs. 2018; 74(2):407–24. Epub 2017/08/24. https://doi.org/10.1111/jan.13444 PMID: 28833356.

4. Xie T, Ye J, Rerkasem K, Mani R. The venous ulcer continues to be a clinical challenge: an update. Burns Trauma. 2018; 6:18. Epub 2018/06/27. https://doi.org/10.1186/s41038-018-0119-y PMID: 29942813.

5. Pastar I, Wong LL, Egger AN, Tomic-Canic M. Descriptive vs mechanistic scientific approach to study wound healing and its inhibition: Is there a value of translational research involving human subjects? Exp Dermatol. 2018; 27(5):551–62. Epub 2018/04/17. https://doi.org/10.1111/exd.13663 PMID: 29660181.

6. Meier NT, Haslam IS, Pattwell DM, Zhang GY, Emelianov V, Paredes R, et al. Thyrotropin-releasing hormone (TRH) promotes wound re-epithelialisation in frog and human skin. PLoS One. 2013; 8(9): e73596. https://doi.org/10.1371/journal.pone.0073596 PMID: 24023889.

7. Stojadinovic O, Tomic-Canic M. Human ex vivo wound healing model. Methods Mol Biol. 2013; 1037:255–64. Epub 2013/09/14. https://doi.org/10.1007/978-1-62703-505-7_14 PMID: 24029940.

8. Deshayes N, Bloas F, Boisso M, Lecardonne J, Paris M. 3D in vitro model of the re-epithelialization phase in the wound-healing process. Exp Dermatol. 2018; 27(5):460–2. Epub 2017/06/13. https://doi.org/10.1111/exd.13390 PMID: 28603853.

9. Eming SA, Tomic-Canic M. Updates in wound healing: Mechanisms and translation. Exp Dermatol. 2017; 26(2):97–8. https://doi.org/10.1111/exd.13281 PMID: 28133858.

10. Garcia CL, Ansell DM. The battle of the bulge: re-evaluating hair follicle stem cells in wound repair. Exp Dermatol. 2017; 26(2):101–4. Epub 2016/08/31. https://doi.org/10.1111/exd.13184 PMID: 27574799.

11. Bekes D, Schmidt T, Napp M, Kerner W, von Woedtke T, et al. Distinct cytokine and chemokine patterns in chronic diabetic ulcers and acute wounds. Exp Dermatol. 2017; 26(2):145–7. Epub 2016/09/28. https://doi.org/10.1111/exd.13215 PMID: 27673417.

12. Lebonvallet N, Lavender B, Desmouliere A, Girard D. New insights into the roles of myofibroblasts and innervation during skin healing and innovative therapies to improve scar innervation. Exp Dermatol. 2018; 27(9):950–8. Epub 2018/05/10. https://doi.org/10.1111/exd.13681 PMID: 29742295.

13. Silva WN, Prazeres P, Paiva AE, Lousado L, Turquetti AOM, Barreto RSN, et al. Macrophage-derived GPNMB accelerate skin healing. Exp Dermatol. 2018; 27(6):630–5. Epub 2018/03/06. https://doi.org/10.1111/exd.13524 PMID: 29505115.

14. Choi EW, Seo MK, Woo EY, Kim SH, Park EJ, Kim S. Exosomes from human adipose-derived stem cells promote proliferation and migration of skin fibroblasts. Exp Dermatol. 2018; 27(10):1170–2. Epub 2017/09/25. https://doi.org/10.1111/exd.13451 PMID: 28940813.

15. Harm HI, Ogawa R, Hsu CK, Hughes MW, Tang MJ, Chuong CM. The tension biology of wound healing. Exp Dermatol. 2017; 26(11):1107–10. https://doi.org/10.1111/exd.13460 PMID: 29103165.

16. Paus R. Exploring the “thyroid-skin connection” : concepts, questions, and clinical relevance. J Invest Dermatol. 2010; 130(1):7–10. https://doi.org/10.1038/jid.2009.359 PMID: 20010860.

17. Freinkel RK, Freinkel N. Hair growth and alopecia in hypothyroidism. Arch Dermatol. 1972; 106(3):349–52. PMID: 5055094.

18. van Beek N, Bodo E, Kromminga A, Gaspar E, Meyer K, Zmijewski MA, et al. Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. J Clin Endocrinol Metab. 2008; 93(11):4381–8. https://doi.org/10.1210/jc.2008-0283 PMID: 18728176.
20. Kaplan MM, Pan CY, Gordon PR, Lee JK, Gilchrest BA. Human epidermal keratinocytes in culture convert thyroxine to 3,5,3'-triiodothyronine by type II iodothyronine deiodination: a novel endocrine function of the skin. J Clin Endocrinol Metab. 1988; 66(4):815–22. https://doi.org/10.1210/jcem-66-4-815 PMID: 2450104.

21. Messenger AG. Thyroid hormone and hair growth. Br J Dermatol. 2000; 142(4):633–4. PMID: 10792210.

22. Safer JD, Fraser LM, Ray S, Holick MF. Topical triiodothyronine stimulates epidermal proliferation, dermal thickening, and hair growth in mice and rats. Thyroid. 2001; 11(8):717–24. https://doi.org/10.1089/105072501S2484547 PMID: 11525263.

23. Bodo E, Kany B, Gaspar E, Knuver J, Kromminga A, Ramot Y, et al. Thyroid-stimulating hormone, a novel, locally produced modulator of human epidermal functions, is regulated by thyrotropin-releasing hormone and thyroid hormones. Endocrinology. 2010; 151(4):1633–42. https://doi.org/10.1210/en.2009-0306 PMID: 20176727.

24. Bodo E, Kromminga A, Biro T, Borbiro I, Gaspar E, Zmijewski MA, et al. Human female hair follicles are a direct, nonclassical target for thyroid-stimulating hormone. J Invest Dermatol. 2009; 129(5):1126–39. https://doi.org/10.1038/jid.2008.361 PMID: 19052559.

25. Olah A, Gherardini J, Bertolini M, Cheret J, Ponce L, Kloepper J, et al. The Thyroid Hormone Analogue KB2115 (Eprotirome) Prolongs Human Hair Growth (Anagen) Ex Vivo. J Invest Dermatol. 2016; 136(8):1711–4. https://doi.org/10.1016/j.jid.2016.03.033 PMID: 2766887.

26. Vidalis S, Cheret J, Giesen M, Haeger S, Alam M, Watson REB, et al. Thyroid Hormones Enhance Mitochondrial Function in Human Epidermis. J Invest Dermatol. 2016; 136(10):2003–12. https://doi.org/10.1016/j.jid.2016.05.118 PMID: 27349864.

27. Vidalis S, Knuver J, Lerchner J, Giesen M, Biro T, Klinger M, et al. Hypothalamic-pituitary-thyroid hormones stimulate mitochondrial function and biogenesis in human hair follicles. J Invest Dermatol. 2014; 134(1):33–42. https://doi.org/10.1038/jid.2013.286 PMID: 23949722.

28. Holt PJ. In vitro responses of the epidermis to triiodothyronine. J Invest Dermatol. 1978; 71(3):202–4. PMID: 690484.

29. Holt PJ, Marks R. The epidermal response to change in thyroid status. J Invest Dermatol. 1977; 68(5):299–301. PMID: 870564.

30. Paus R, Griffiths Ce, Barker JMDe, Bleiker Te, Chalmers Re, Creamer De, et al. Rook’s Textbook of dermatology. Ninth edition. ed2017. p. 149.1–23.

31. Erdogan M, Ilhan YS, Akkus MA, Caboglu SA, Ozercan I, Ilhan N, et al. Effects of L-thyroxine and zinc therapy on wound healing in hypothyroid rats. Acta Chir Belg. 1999; 99(2):72–7. PMID: 10352736.

32. Safer JD, Crawford TM, Holick MF. Topical thyroid hormone accelerates wound healing in mice. Endocrinology. 2005; 146(10):4425–30. https://doi.org/10.1210/en.2005-0192 PMID: 15976059.

33. Kress E, Samarut J, Plateroti M. Thyroid hormones and the control of cell proliferation or cell differentiation: paradox or duality? Mol Cell Endocrinol. 2009; 313(1–2):36–49. https://doi.org/10.1016/j.mce.2009.08.028 PMID: 19737599.

34. Nygaard B, Saedder EA, Dalhoff K, Wikkelsoe M, Jurgens G. Levothyroxine Poisoning—Symptoms and Clinical Outcome. Basic Clin Pharmacol Toxicol. 2015; 117(4):280–5. Epub 2015/03/31. https://doi.org/10.1111/bcpt.12401 PMID: 25816846.

35. Ito M, Yang Z, Andl T, Cui C, Kim N, Millar SE, et al. Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature. 2007; 447(7193):316–20. https://doi.org/10.1038/nature05766 PMID: 17507982.

36. Ansell DM, Kloepper JE, Thomason HA, Paus R, Hardman MJ. Exploring the "hair growth-wound healing connection": anagen phase promotes wound re-epithelialization. J Invest Dermatol. 2011; 131(2):518–28. https://doi.org/10.1038/jid.2010.291 PMID: 20927125.

37. Jimenez F, Poblet E, Izeta A. Reflections on how wound healing-promoting effects of the hair follicle can be translated into clinical practice. Exp Dermatol. 2015; 24(2):91–4. Epub 2014/07/30. https://doi.org/10.1111/exd.12521 PMID: 25066054.

38. Lu Z, Hasse S, Bodo E, Rose C, Funk W, Paus R. Towards the development of a simplified long-term organ culture method for human scalp skin and its appendages under serum-free conditions. Exp Dermatol. 2007; 16(1):37–44. https://doi.org/10.1111/j.1600-0625.2006.00510.x PMID: 17181635.

39. Moll I, Houdek P, Schmidt H, Moll R. Characterization of epidermal wound healing in a human skin organ culture model: acceleration by transplanted keratinocytes. J Investig Dermatol. 1998; 111(2):251–8. https://doi.org/10.1046/j.1523-1747.1998.00265.x PMID: 9699726.

40. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008; 453(7193):314–21. https://doi.org/10.1038/nature07039 PMID: 18480812.
41. Raja, Sivamani K, Garcia MS, Isseroff RR. Wound re-epithelialization: modulating keratinocyte migration in wound healing. Front Biosci. 2007; 12:2849–68. PMID: 17485264.

42. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999; 341(10):738–46. https://doi.org/10.1056/NEJM199909023411006 PMID: 10471461.

43. Abramo F, Pirone A, Lenzi C, Vannozzi I, Della Valle MF, Miragliaotta V. Establishment of a 2-week canine skin organ culture model and its pharmacological modulation by epidermal growth factor and dexamethasone. Ann Anat. 2016; 207:109–17. Epub 2016/04/09. https://doi.org/10.1016/j.aanat.2016.03.009 PMID: 27058637.

44. Mecklenburg L, Tobin DJ, Muller-Rover S, Handjiski B, Wendt G, Peters EM, et al. Active hair growth (anagen) is associated with angiogenesis. J Invest Dermatol. 2000; 114(5):909–16. https://doi.org/10.1046/j.1523-1747.2000.00954.x PMID: 10771470.

45. Davis FB, Mousa SA, O'Connell L, Mohamed S, Lin HY, Cao HJ, et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res. 2004; 94(11):1500–6. https://doi.org/10.1161/01.RES.0000130784.90237.4a PMID: 15117822.

46. Cao Y, Arbiser J, D’Amato RJ, D’Amore PA, Ingber DE, Kerbel R, et al. Forty-year journey of angiogenesis translational research. Sci Transl Med. 2011; 3(114):114 rv3. https://doi.org/10.1126/scitranslmed.3003149 PMID: 22190240.

47. Choi SM, Lee KM, Kim HJ, Park IK, Kang HJ, Shin HC, et al. Effects of structurally stabilized EGF and bFGF on wound healing in type I and type II diabetic mice. Acta Biomater. 2018; 66:325–34. Epub 2017/12/06. https://doi.org/10.1016/j.actbio.2017.11.045 PMID: 29288809.

51. Oguno S, Morimoto N, Sakamoto M, Jinno C, Sakamoto Y, Sato Y, et al. Protective effect of FGF-2 and low-molecular-weight heparin/protamine nanoparticles on radiation-induced healing-impaired wound repair in rats. J Radiat Res. 2018; 59(1):27–34. Epub 2017/11/10. https://doi.org/10.1093/jrr/rwx044 PMID: 29121251.

53. Shamseldin A, Sarmadi M, Aghababaie Z, Vossoughi M. Accelerated full-thickness wound healing via sustained bFGF delivery based on a PVA/chitosan/gelatin hydrogel incorporating PCL microspheres. Int J Pharm. 2018, 537(1–2):278–89. Epub 2017/12/31. https://doi.org/10.1016/j.ijpharm.2017.12.045 PMID: 29229125.

55. Ogino S, Morimoto N, Sakamoto M, Jinno C, Sakamoto Y, Taira T, et al. Efficacy of the dual controlled release of HGF and bFGF impregnated with a collagen/gelatin scaffold. J Surg Res. 2018; 221:173–82. Epub 2017/12/13. https://doi.org/10.1016/j.jss.2017.08.051 PMID: 29229125.

57. Sajio H, Kilpadi DV, Akita S. Evaluation of the use of recombinant human basic fibroblast growth factor in combination with negative pressure wound therapy with instillation and dwell time in porcine full-thickness wound model. Wound Repair Regen. 2017; 25(6):372–5. Epub 2018/01/13. https://doi.org/10.1111/wrr.12609 PMID: 29328528.

59. Roseth JD, Coulombe PA. A wound-induced keratin inhibits Src activity during keratinocyte migration and tissue repair. J Cell Biol. 2012; 197(3):381–9. https://doi.org/10.1083/jcb.201107076 PMID: 22529101.

61. Wong P, Coulombe PA. Loss of keratin 6 (K6) proteins reveals a function for intermediate filaments during wound repair. J Cell Biol. 2003; 163(2):327–37. Epub 2003/10/22. https://doi.org/10.1083/jcb.200305032 PMID: 14568992.

63. Philipott MP, Green MR, Kealey T. Human hair growth in vitro. J Cell Sci. 1990; 97 (Pt 3):463–71. PMID: 1705941.

65. Bodo E, Kromminga A, Funk W, Laugsch M, Duske U, Jelkmann W, et al. Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin. FASEB J. 2007; 21(2):3346–54. https://doi.org/10.1096/fj.07-8628com PMID: 17540710.

67. Bodo E, Tobin DJ, Kamenisch Y, Biro T, Berneburg M, Funk W, et al. Dissecting the impact of chemotheraphy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy. Am J Pathol. 2007; 171(4):1153–67. https://doi.org/10.2353/ajpath.2007.061164 PMID: 17822268.

69. Telek A, Biro T, Bodo E, Toth BI, Borbosi I, Kunos G, et al. Inhibition of human hair follicle growth by endo- and exocannabinoids. FASEB J. 2007; 21(13):3534–41. https://doi.org/10.1096/fj.06-7689com PMID: 17567570.

71. Arbiser JL, Byers HR, Cohen C, Arbej J. Altered basic fibroblast growth factor expression in common epidermal neoplasms: examination with in situ hybridization and immunohistochemistry. J Am Acad Dermatol. 2000; 42(6):973–7. PMID: 10827398.
60. Knuever J, Poeggeler B, Gaspar E, Klinger M, Hellwig-Burgel T, Hardenbicker C, et al. Thyrotropin-releasing hormone controls mitochondrial biology in human epidermis. J Clin Endocrinol Metab. 2012; 97(3):978–86. https://doi.org/10.1210/jc.2011-1096 PMID: 22259067.

61. Poeggeler B, Knuever J, Gaspar E, Biro T, Klinger M, Bodo E, et al. Thyrotropin powers human mitochondria. FASEB J. 2010; 24(5):1525–31. https://doi.org/10.1096/fj.09-147728 PMID: 20705194.

62. Stenn KS. Epibolin: a protein of human plasma that supports epithelial cell movement. Proc Natl Acad Sci U S A. 1981; 78(11):6907–11. PMID: 6171824.

63. Wojcik SM, Bundman DS, Roop DR. Delayed wound healing in keratin 6a knockout mice. Mol Cell Biol. 2000; 20(14):5248–55. PMID: 10866680.

64. Luidens MK, Mousa SA, Davis FB, Lin HY, Davis PJ. Thyroid hormone and angiogenesis. Vasc Pharmacol. 2010; 52(3–4):142–5. https://doi.org/10.1016/j.vph.2009.10.007 PMID: 19879961.

65. Martinez ML, Escario E, Poblet E, Sanzquez D, Buchon FF, Izeta A, et al. Hair follicle-containing punch grafts accelerate chronic ulcer healing: A randomized controlled trial. J Am Acad Dermatol. 2016; 75(5):1007–14. https://doi.org/10.1016/j.jaad.2016.02.1161 PMID: 27745629.

66. Poblet E, Jimenez F, Escario-Travesedo E, Hardman JA, Hernandez-Hernandez I, Agudo-Mena JL, et al. Eccrine sweat glands associate with the human hair follicle within a defined compartment of dermal white adipose tissue. Br J Dermatol. 2018; 178(5):1163–72. Epub 2018/02/13. https://doi.org/10.1111/bjd.16436 PMID: 29432654.

67. Cheret J, Bertolini M, Ponce L, Lehmann J, Tsai T, Alam M, et al. Olfactory receptor OR2AT4 regulates human hair growth. Nat Commun. 2018; 9(1):3624. Epub 2018/09/20. https://doi.org/10.1038/s41467-018-05973-0 PMID: 30228264.

68. Hawkshaw NJ, Hardman JA, Haslam IS, Shahmalak A, Gilhar A, Lim X, et al. Identifying novel strategies for treating human hair loss disorders: Cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles. PLoS Biol. 2018; 16(5):e2003705. Epub 2018/05/09. https://doi.org/10.1371/journal.pbio.2003705 PMID: 29738529.

69. Orlandi C, Bondioli E, Venturi M, Melandri D. Preliminary observations of a new approach to tissue repair: Peripheral blood mononuclear cells in platelet-rich plasma injected into skin graft area. Exp Dermatol. 2018; 27(7):795–7. Epub 2018/04/01. https://doi.org/10.1111/exd.13552 PMID: 29604139.

70. Takagi N, Kawakami K, Kanno E, Tanno H, Takeda A, Ishii K, et al. IL-17A promotes neutrophilic inflammation and disturbs acute wound healing in skin. Exp Dermatol. 2017; 26(2):137–44. Epub 2016/06/16. https://doi.org/10.1111/exd.13115 PMID: 27305096.

71. Sugawara K, Biro T, Tsuruta D, Kromminga A, Zakany N, et al. Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol. 2012; 129(3):726–38 e8. Epub 2012/01/10. https://doi.org/10.1016/j.jaci.2011.11.009 PMID: 22226549.

72. Cappellano G, Morandi EM, Rainer J, Grubwieser P, Heinz K, Wolfram D, et al. Human Macrophages Preferentially Infiltrate the Superficial Adipose Tissue. Int J Mol Sci. 2018; 19(5). Epub 2018/05/09. https://doi.org/10.3390/ijms19051404 PMID: 28843624.

73. Suga 74. Sugawara K, Biro T, Tsuruta D, Toth Bl, Kromminga A, Zakany N, et al. Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol. 2012; 129(3):726–38 e8. Epub 2012/01/10. https://doi.org/10.1016/j.jaci.2011.11.009 PMID: 22226549.

75. Ambr 76. Gabrino F, Lazzarini G, Pirone A, Lenzi C, Albertini S, Della Valle MF, et al. Ultramicronized palmitoyl-llethanolamide counteracts the effects of compound 48/80 in a canine skin organ culture model. Vet Dermatol. 2017; 28(5):456–e104. Epub 2017/06/07. https://doi.org/10.1111/vde.12456 PMID: 28585337.

77. Poursa 78. Markova A, Mostow EN. US skin disease assessment: ulcer and wound care. Dermatol Clin. 2012; 30(1):107–11, ix. https://doi.org/10.1016/j.det.2011.08.005 PMID: 22117872.

79. Pourmay Y, Roland IH, Leclercq-Smekens M, Leloup R. Basal detachment of the epidermis using disease: tissue spatial organization and fate of integrin alpha 6 beta 4 and hemidesmosomes. J Invest Dermatol. 1994; 102(1):111–7. PMID: 8288902.